These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1118 related items for PubMed ID: 16802350

  • 1. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, ATLAS Study Group.
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, Wu H, Wang G, Shi Q, Andhivarothai N, Anderson J, Pangan AL.
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, Thomson GT, Beaulieu A, Choquette D, Maksymowych WP.
    Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
    Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC, ATLAS Study Group.
    J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD, Maksymowych WP, CANDLE Study Group.
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [Abstract] [Full Text] [Related]

  • 7. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
    van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, Davis JC, Wong RL, Kupper H, Collantes E, ATLAS Study Group.
    Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755
    [Abstract] [Full Text] [Related]

  • 8. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 9. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP.
    Arthritis Rheum; 2007 Aug 15; 57(6):1050-7. PubMed ID: 17665483
    [Abstract] [Full Text] [Related]

  • 10. [A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis].
    Huang F, Zhang J, Zheng Y, Xu JH, Li XF, Wu HX, Chen ZW, Zhao Z, Zhang YM.
    Zhonghua Nei Ke Za Zhi; 2011 Dec 15; 50(12):1043-7. PubMed ID: 22333175
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
    Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2008 Sep 15; 59(9):1270-8. PubMed ID: 18759257
    [Abstract] [Full Text] [Related]

  • 12. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group.
    Arthritis Rheum; 2003 Nov 15; 48(11):3230-6. PubMed ID: 14613288
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
    Arthritis Rheum; 2005 Oct 15; 52(10):3279-89. PubMed ID: 16200601
    [Abstract] [Full Text] [Related]

  • 14. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J.
    Arthritis Rheum; 2010 May 15; 62(5):1290-7. PubMed ID: 20461780
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.
    Dougados M, Luo MP, Maksymowych WP, Chmiel JJ, Chen N, Wong RL, Davis JC, van der Heijde D, ATLAS STUDY GROUP.
    Arthritis Rheum; 2008 Apr 15; 59(4):553-60. PubMed ID: 18383418
    [Abstract] [Full Text] [Related]

  • 16. Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics.
    Maksymowych WP, Gooch K, Dougados M, Wong RL, Chen N, Kupper H, van der Heijde D.
    Arthritis Care Res (Hoboken); 2010 Jun 15; 62(6):826-34. PubMed ID: 20535793
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.
    Ann Rheum Dis; 2004 Dec 15; 63(12):1594-600. PubMed ID: 15345498
    [Abstract] [Full Text] [Related]

  • 18. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study).
    Navarro-Sarabia F, Fernández-Sueiro JL, Torre-Alonso JC, Gratacos J, Queiro R, Gonzalez C, Loza E, Linares L, Zarco P, Juanola X, Román-Ivorra J, Martín-Mola E, Sanmartí R, Mulero J, Diaz G, Armendáriz Y, Collantes E.
    Rheumatology (Oxford); 2011 Oct 15; 50(10):1828-37. PubMed ID: 21700683
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
    Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, Wong RL, Inman RD, M03-606 Study Group.
    J Rheumatol; 2008 Oct 15; 35(10):2030-7. PubMed ID: 18785308
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
    Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S.
    J Rheumatol; 2009 Apr 15; 36(4):801-8. PubMed ID: 19273449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.